Table 2.
Risk factors for renal disease in trial participants after the intervention
| Kumamoto | UKPDS 33 | UKPDS 34 | VA Diabetes Feasibility Trial |
ACCORD | ADVANCE | VADT | |
|---|---|---|---|---|---|---|---|
| Median HbA1C (%) | |||||||
| Intensive | 7.1 | 7.0 | 7.4 | 7.1 | 6.4 | 6.5 | 6.9 |
| Standard | 9.4 | 7.9 | 8.0 | 9.1 | 7.5 | 7.3 | 8.4 |
| Mean LDL (mmol/L) | |||||||
| Intensive | … | 3.26 | 3.37 | … | 2.59 | 2.64 | 2.07 |
| Standard | … | 3.26 | 3.34 | … | 2.61 | 2.65 | 2.07 |
| Mean SBP (mm Hg) | |||||||
| Intensive | … | 139 | 141 | 135 | 135 | 135.5 | 127 |
| Standard | … | 138 | 139 | 142 | 135 | 138 | 125 |
| Mean DBP (mm Hg) | |||||||
| Intensive | … | 77 | 78 | 82 | 75 | 73.5 | 68 |
| Standard | … | 77 | 77 | 82 | 75 | 74.3 | 69 |
…= Not Reported
Abbreviations: SBP- systolic blood pressure, DBP- diastolic blood pressure, LDL- low density lipoprotein